Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.53 on revenue of $2.53M. Analysts polled by Investing.com anticipated EPS of $-0.57 on revenue of $2M.
Nabriva Therapeutics shares are up 32% from the beginning of the year, still down 87.58% from its 52 week high of $12.00 set on May 29, 2020. They are outperforming the S&P 500 which is up 11.86% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on April 20, who reported EPS of $2.59 on revenue of $22.32B, compared to forecasts EPS of $2.34 on revenue of $21.98B.
Pfizer had beat expectations on Tuesday with first quarter EPS of $0.93 on revenue of $14.58B, compared to forecast for EPS of $0.7773 on revenue of $13.67B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar